China’s new national action plan to combat antimicrobial resistance (2022–25)

作者：Li Ding, Fupin Hu · 发表于：Journal of Antimicrobial Chemotherapy · 年份：2022 · DOI：10.1093/jac/dkac435 · 被引用次数：29 · 研究领域：Antibiotic Use and Resistance、Antibiotic Resistance in Bacteria、Pneumonia and Respiratory Infections

Antimicrobial resistance (AMR) is a major challenge for global public health, and the wide spread of MDR organisms brings a heavy economic burden to infected patients, especially those in developing countries or low-resource countries or regions; this is a global problem of wide concern to governments and society.1 The WHO has been calling on countries to pay attention to the threat of AMR for many years, and important international meetings such as the General Assembly of the United Nations, the World Health Assembly, and the G20 Summit have repeatedly studied and discussed AMR.2,3 In 2016, in response to the global action plan on AMR issued by the WHO, 14 ministries and commissions of the Chinese government jointly issued a national action plan for combating AMR (2016–20), which adopted comprehensive management measures at the national level and strengthened regulation in all aspects of drug research and development, production, distribution, application and environmental protection.4 To further strengthen efforts to combat AMR and actively respond to international and domestic concerns, the Chinese government recently announced a new national action plan, the ‘National Action Plan for Combating Antimicrobial Resistance (2022–2025)’ in October 2022.5 The action plan, led by the National Health Commission in conjunction with 12 ministries and commissions, focuses on the need to effectively control major pathogens of human and animal origin and gives new annual targets and mo...